2022
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC
Kim SY, Herbst RS. BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC. Nature Reviews Clinical Oncology 2022, 20: 3-4. PMID: 36271141, DOI: 10.1038/s41571-022-00698-y.Peer-Reviewed Original ResearchConceptsCell lung cancerTumor mutational burdenLung cancerMutational burdenBlood-based tumor mutational burdenAdvanced-stage solid tumorsFirst phase III trialHigh tumor mutational burdenImmune checkpoint inhibitorsPhase III trialsIII trialsPredictive biomarkersExploratory biomarkersCompanion biomarkersSolid tumorsBiomarkersCancerBurdenPembrolizumabNSCLCPatientsTumorsTrials
2009
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
William WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nature Reviews Clinical Oncology 2009, 6: 132-133. PMID: 19190590, DOI: 10.1038/ncponc1321.Peer-Reviewed Original ResearchAdvanced squamous cell carcinomaSquamous cell carcinomaCell carcinomaFirst phase III trialChemotherapy-alone armMedian overall survivalPrimary end pointPhase III trialsCetuximab armCetuximab therapyUntreated patientsIII trialsOverall survivalCurative treatmentCurable diseasePredictive markerSurvival advantageClinical practiceCetuximabPatientsEnd pointEXTREME trialTrialsChemotherapyCarcinoma